Last reviewed · How we verify
NCT05512039: RELIEF
Reduced-dose Botox for Urgency Incontinence Among Elder Females
Phase 1, PHASE2 trial testing Botox 50 Unit Injection in Overactive Bladder in 376 participants. Participants enrolled and being followed up; not accepting new ones.
1 September 2026
Quick facts
| Lead sponsor | Dartmouth-Hitchcock Medical Center |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 376 |
| Start date | 12 May 2023 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 January 2027 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- Botox 50 Unit Injection — full drug profile →
- Botox 100 Unit Injection — full drug profile →
Conditions studied
- Overactive Bladder — all drugs for Overactive Bladder →
- Urinary Incontinence in Old Age — all drugs for Urinary Incontinence in Old Age →
- Urgency Urinary Incontinence — all drugs for Urgency Urinary Incontinence →
Sponsor
Dartmouth-Hitchcock Medical Center
Who can join
70 and older, female only, with Overactive Bladder or Urinary Incontinence in Old Age. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard dose of onabotulinumtoxinA (BTX; trade name BOTOX(c)) injection in the bladder.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05512039
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Overactive Bladder
Currently open trials in the same condition.
- NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
- NCT05895045 — Yoga for Treatment of Overactive Bladder in Pediatric Patients · NA · recruiting
- NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
- NCT06921746 — Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients · recruiting
- NCT06935240 — Investigation of Effects of Electrical Stimulation in Women With Vaginal Laxity · NA · recruiting
Other Dartmouth-Hitchcock Medical Center trials
Trials by the same sponsor.
- NCT07325474 — Plan and Protect: Safety Planning for Teens in Rural Emergency Departments · NA · not yet recruiting
- NCT07428629 — Piloting an Insomnia Treatment in Patients With Ulcerative Colitis · NA · not yet recruiting
- NCT06777511 — Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients · not yet recruiting
- NCT07279116 — ABY-029 Head & Neck Trial · Phase 1 · not yet recruiting
- NCT07063693 — ABY-029 Glioma Trial · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05512039 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center
- Last refreshed: 3 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05512039.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing